• Envoy Medical posted Q2 net revenue of USD 51,000, down 34.62% from USD 78,000 a year earlier.
• Net loss attributable to common stockholders widened to USD 7.27 million, or USD 0.07 per share, from USD 6.94 million, or USD 0.32.
• R&D expense climbed 26.04% to USD 3.13 million, driven by clinical-trial follow-up activity, PMA module submission fees, and personnel costs.
• Cash totaled about USD 19.68 million at June 30, 2026, up from USD 3.74 million at Dec. 31, 2025.
• Submitted the first of four modular PMA modules to the FDA for the Acclaim cochlear implant; final module with clinical data targeted for Q2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envoy Medical Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608100800NEWSFILECNPR____20260810_308813_1) on August 10, 2026, and is solely responsible for the information contained therein.